Home › Meningioma › North Carolina
Meningioma clinical trials in North Carolina
6 studies for Meningioma are looking for participants at sites in North Carolina.
Cities in North Carolina
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
- Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06955169Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT02523014A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
- Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07533942A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Duke University, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07428616Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- University of North Carolina, Chapel Hill
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Oct 13, 2026 · NCT05636618Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Vidant Heath - ECU Medical Center, Greenville
- Atlantic Brain & Spine, Wilmington
RecruitingObservational study
All ages · All sexes · Updated Jul 22, 2026 · NCT04427384From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.